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Abstract
Introduction: Although ruptured atherosclerotic plaques have been extensively analyzed, the composition of thrombi
causing arterial occlusion in patients with ST-segment elevation acute myocardial infarction has been less thoroughly
investigated. We sought to investigate whether coagulant active tissue factor can be retrieved in thrombi of patients with
STEMI undergoing primary percutaneous coronary intervention.
Methods: Nineteen patients with ST-segment elevation acute myocardial infarction referred for primary percutaneous
coronary intervention were enrolled in this study. Coronary thrombi aspirated from coronary arteries were routinely
processed for paraffin embedding and histological evaluation (4 patients) or immediately snap frozen for evaluation of
tissue factor activity using a modified aPTT test (15 patients). Immunoprecipitation followed by immunoblotting was also
performed in 12 patients.
Results: Thrombi aspirated from coronary arteries showed large and irregular areas of tissue factor staining within platelet
aggregates, and in close contact with inflammatory cells. Some platelet aggregates stained positive for tissue factor,
whereas others did not. Monocytes consistently stained strongly for tissue factor, neutrophils had a more variable and
irregular tissue factor staining, and red blood cells did not demonstrate staining for tissue factor. Median clotting time of
plasma samples containing homogenized thrombi incubated with a monoclonal antibody that specifically inhibits tissue
factor-mediated coagulation activity (mAb 5G9) were significantly longer than their respective controls (88.9 seconds versus
76.5 seconds, respectively; p,0.001). Tissue factor was also identified by immunoprecipitation in 10 patients, with
significant variability among band intensities.
Conclusions: Active tissue factor is present in coronary artery thrombi of patients with ST-segment elevation acute
myocardial infarction, suggesting that it contributes to activate the coagulation cascade ensuing in coronary thrombosis.
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Introduction
ST-segment elevation myocardial infarction (STEMI) is one of
the leading causes of mortality and morbidity in the western world
[1]. There is increasing evidence that STEMI is in most cases
precipitated by rupture of thin cap fibroatheromas, and that the
exposure of procoagulant material contained in the plaque to
circulating blood initiates platelet aggregation, thrombin genera-
tion and fibrin deposition ultimately leading to coronary
thrombosis [2]. However, while ruptured atherosclerotic plaques
have been extensively analyzed [3,4,5], the composition of
thrombi causing arterial occlusion has been less thoroughly
investigated.
Tissue factor (TF) is a glycoprotein that serves as the initiator of
the coagulation cascade. TF binds the serine protease factor VII to
activate factor X, leading to thrombin generation and thrombus
formation [6]. Alternatively, TF can bind protease-activated
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receptors (PARs) to signal inflammation and tumorigenesis [7,8].
TF is normally localized in extracellular spaces such as in
adventitial cells of blood vessels, epidermal cells of skin, fibrous
capsule, and stromal cells, thus providing a continuous hemostatic
barrier ready to initiate the coagulation cascade upon vessel wall
integrity disruption [9]. TF is therefore considered a major
regulator of coagulation, haemostasis, and thrombosis [10]. TF
antigen has also been identified in atherosclerotic plaques
[4,11,12], but less is known about its presence and activity in
thrombosis during STEMI. In this study we analyzed the presence
of TF antigen and its coagulation activity in thrombi harvested
from coronary arteries of patients with STEMI referred for
primary percutaneous coronary intervention (PCI).
Methods
Ethic Statement
The present clinical investigation was conducted according to
the principles expressed in the Declaration of Helsinki. The study
was approved by the ethics committee of Policlinico S.Orsola of
Bologna, and all patients provided written informed consent to
participate in the study.
Design and Patient Selection
Patients were eligible for participation if they were aged 18 years
or older, presented within 12 hours after the onset of symptoms,
had ST-segment elevation of 1 mm or more in 2 or more
contiguous leads, had a total coronary occlusion (TIMI flow=0),
and were candidates for thrombus aspiration with a manual
thrombectomy device. Exclusion criteria were the presence of
cardiogenic shock or inability to obtain written informed consent.
The study consisted of 2 groups: in the first group (4 patients),
thrombi harvested from coronary arteries were paraffin embedded
and the presence of TF antigen was evaluated by immunohisto-
chemistry. In the second group (15 patients), thrombi were snap
frozen in liquid nitrogen and subsequently analyzed with clotting
assays to assess the presence of TF activity.
Reagents
Pooled normal human plasma was prepared from blood
collected into 4 ml vacuum tubes containing sodium citrate
(3.2%) from 15 healthy volunteers. Blood was immediately
centrifuged at 3,000 g610 minutes at room temperature.
Plasma samples were then pooled, aliquoted, and frozen at
220uC. Tris-buffer saline (TBS) was prepared using 50 mM
Tris-HCl, 150 mM NaCl, pH 7.4. Antibodies were described
previously [8,13,14]. Monoclonal antibody (mAb) 5G9 inhibits
coagulation activity of TF [8,15]; mAb 10H10 recognizes the
noncoagulant, cryptic conformation of TF, inhibiting TF-VIIa
mediated signaling via PAR2 [16]. Although mAb 5G9 reacts
with both coagulant and cryptic forms of TF on cells, it does
not inhibit TF-VIIa signalling. In sharp contrast, mAb 10H10
shows poor reactivity towards coagulant active TF, but
efficiently blocks TF-VIIa signaling. TF mAb 9C3 and affinity
purified goat anti-TF antibodies were described previously by
Ahamed et al [16]. The anti-TF mAb CD 142 is specific for
aminoacids 1–25 within the extracellular domain (American
Diagnostica, Stamford, CT). Chromo Pure mouse IgG was from
Jackson Immunoresearch Labs Inc. (West Grove, PA). Com-
mercial thromboplastin (RecombiPlasTin 2G, Instrumentation
Laboratory, Bedford, MA) was used to determine prothrombin
times in control experiments.
PCI Procedure
PCI was performed according to standard technique. After
wiring the coronary obstruction, coronary thrombi were aspirated
using a manual thrombectomy device (ELIMINATE, Terumo
Clinical Supply, Kakamigahara, Japan). The aspiration catheter
was passed through the coronary obstruction 3 times, starting the
aspiration right before the obstruction. All patients were given
aspirin 250 mg intravenously, and heparin 70 U/kg before
thrombus aspiration. Use of glycoprotein IIb/IIIa inhibitors as
well as stent choice was left at physician’s discretion. A loading
dose of clopidogrel 600 mg was administered at the end of the
procedure in all patients.
Coronary Thrombi
Thrombi aspirated from coronary arteries were harvested using
a filter basket supplied by the manufacturer of the aspiration
device, and then either snap frozen in liquid nitrogen and stored at
280u until analysis, or immediately fixed in formalin. The day of
analysis, snap frozen thrombi were homogenized using a tissue
homogenizer (Wheaton Industries Inc, Millville, NJ), and
resuspended in TBS. The protein concentrations were adjusted
to 10 mg/ml. Then, 20 ml was used for the clotting assay, and the
remainder volume lysed for immunoprecipitation followed by
immunoblotting. Formalin-fixed thrombi were processed for
histologic analysis.
Histology and Immunohistochemistry
Thrombus aspirate specimens were fixed in 10% paraformal-
dehyde, and paraffin embedded. From each paraffin block,
sections (2 mm) were cut and stained with haematoxylin-eosin
and Azan-Mallory trichrome. Immunohistochemistry was per-
formed using 2 different antibodies: CD142 (dilution 1:250) and
10H10 (dilution 1:100). For CD142 immunostaining, sections
were treated with citrate buffer, pH 6.0 at 98uC for 40 minutes.
Anti-CD142 immunostaining was done with DakoCytomation
autostainer using Dako Advance visualization System. For 10H10
staining, sections were treated with Tris-EDTA buffer, pH 9.0 at
98uC for 20 minutes. Anti-10H10 immunoperoxidase staining was
manually performed with overnight incubation at room temper-
ature using Novolink visualization system (Novocastra Laborato-
ries, Newcastle UK). A negative control was performed using an
isotype-matched irrelevant primary antibody (mouse IgG anti-
epithelial membrane antigen; Ventana Medical Systems, Inc,
Tucson, AZ).
Clotting Assay
TF activity of homogenized thrombi was analyzed using a
modified activated partial thromboplastin time (aPTT) test in an
automated optical instrument (ACL ADVANCE, Instrumentation
Laboratory, Milan, Italy). Pooled normal human plasma (60 ml)
was incubated with homogenized thrombi solution (10 ml) with or
without mAb 5G9 (300 mg/ml final concentration) for 10 minutes
at room temperature. Then, 100 ml of liquid rabbit cephalin
(ACTIN, Siemens Healthcare diagnostic, Marburg, Germany),
diluted 1:1 with 0.025 mol/L CaCl2 was added and the time to
coagulation measured. Control samples included plasma with
buffer, 5G9, 10H10 or IgG. As a quality control we also assessed
the effect of mAb 5G9 on exogenously added TF- mediated
clotting activity using standard prothrombin times.
Immunoprecipitation and Immunoblotting of TF
Proteins from coronary artery thrombi were extracted after
homogenization in buffer containing 50 mM n-octyl b-D-gluco-
Tissue Factor in STEMI
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e81501
pyranoside for 1 hour on ice. TF was immunoprecipitated from
the lysed thrombi using mAb 9C3 coupled to magnetic Dynabeds
(Invitrogen). Immunoblotting was performed with affinity purified
goat anti-TF antibody. Normalization of western blot analysis was
performed by loading the same amount of total proteins (20 mg).
Blots were digitized for densitometry by using ImageJ program
(NIH).
Statistical Analysis
Data are presented as mean 6 SD or median and interquartile
range as appropriate. Normality was checked with the Smirnov-
Kolmogorov test. Continuous data were compared by pairwise
Student t test or Wilcoxon Signed Rank test, as appropriate.
Correlations were evaluated with the Spearman test. Statistical
analyses were performed using Stata/SE 11.2 (StataCorp LP,




Of the 24 patients considered eligible for the study in the period
between February 2012 and August 2012, 5 were excluded
because aspirates did not contain particulate thrombi sufficient for
analyses, and 19 were finally included in the study. The clinical
characteristics of patients enrolled in this study are reported in
Table 1. The median age was 67 years and 12 of the 19 patients
were male. Median time of ischemia was 150 minutes with a range
of 30 to 720 minutes. No major complications occurred during the
procedure and all patients were discharged alive.
Histological Evaluation
Histological evaluation of thrombi aspirated from coronary
arteries of 4 patients with STEMI showed irregular areas of
erythrocytes trapped in a fibrin network with large and irregular
areas of platelet aggregates and clusters of granulocytes and
monocytes (Figure 1A–D). Samples stained with CD142 showed
large and irregular areas of TF within platelet aggregates, and in
close contact with inflammatory cells (Figure 1B and C). Of note,
some platelet aggregates stained positive for TF, whereas others
did not (Figure 1B). Monocytes stained intensely, neutrophils gave
a more variable staining, and red blood cells were negative
(Figure 1D). The negative control for TF staining is provided in
Figure 1E. TF staining with mAb 10H10, which has higher affinity
for the signalling form of TF, showed similar staining pattern as
CD142 (Figure 2). In particular, some platelet aggregates stained
positive for 10H10, whereas other did not (Figure 2A and B).
Monocytes stained strongly, neutrophils weakly, and red blood
cells negatively (figure 2C).
TF Activity in Thrombi of Patients with STEMI
In the quality control experiments, mAb 5G9 inhibited clotting
activity of exogenous TF in a dose dependent manner (data not
shown). In sharp contrast (Figure 3A), no significant difference was
apparent in clotting times of plasma samples not containing
homogeneized thrombi and incubated with either 5G9 (median
116.3 seconds, IQ range 108.6–150.6 seconds), TBS (median
116.3 seconds, IQ range 109.5–150.2 seconds), 10H10 (median
114.2 seconds, IQ range 107.8–150.2 seconds), or an isotype-
matched IgG (median 116.7 seconds, IQ range 108.2–151.1
seconds). All these clotting times were significantly longer when
compared to clotting times of plasma samples containing
homogenized thrombi not incubated with 5G9 (p,0.001).
Clotting times of plasma samples containing homogeneized
thrombi were non normally distributed, varying from 6.4 seconds
to 126.9 seconds in plasma samples containing homogenized
thrombi not incubated with mAb 5G9, and from 8.0 to 160.0
seconds in those incubated with mAb 5G9. Clotting times of
plasma samples containing homogenized thrombi incubated with
5G9 were significantly longer than samples without mAb 5G9
(Figure 3B). In particular, median clotting time was 88.9 seconds
(IQ range 71.9–110.6 seconds) for homogenized thrombi incu-
bated with mAb 5G9 versus 76.5 seconds (IQ range 22.3–101.7
seconds) for homogenized thrombi not incubated with mAb 5G9
(p,0.001). Incubation of thrombi homogenates with mAb 5G9
increased clotting times in 13 out of 15 patients (Table 2 and
Figure 3C). Differences in clotting times (delta clotting time)
between homogenized thrombi incubated with or without the
antibody varied significantly from sample to sample, ranging from
0.9 seconds to 90.1 seconds (Figure 3D).
Western Blot
TF was detected by immunoblotting in 10 out of the 12 patient
samples tested, but the staining intensity varied (Figure 4). Eight
out of 10 samples with detectable TF antigen by immunoblotting
also showed TF coagulant activity. There was no significant
correlation, however, between TF antigen levels measured by
immunoblotting and TF clotting activity measured by aPTT assay,
although a trend was apparent (correlation coefficient = 0.52;
p = 0.08).
Discussion
Our data provide direct evidence that both TF antigen and TF
coagulation activity are present in thrombi isolated from patients
with STEMI. We developed a new method to assess TF activity in
thrombi harvested from patients with STEMI. It uses the same
principle as a conventional aPTT assay, but adds a mAb specific
for TF clotting activity to assess specificity. Control experiments
demonstrated that mAb 5G9 does not affect the clotting times of
plasma samples not containing homogenized thrombi, but inhibits
exogenously added TF.
Clinical and experimental studies have demonstrated the
presence of TF antigen in animal models of stent thrombosis
[17], in human arterial specimens [3,5], and in coronary
atherectomy specimens retrieved from patients with unstable
angina or myocardial infarction [4,11,12]. Some of these studies
have also suggested that TF contained in atherosclerotic plaque is
potentially active [3,4,12]. Although these prior observations
suggest that TF may be an important determinant of plaque
thrombogenicity, no study has ever provided direct evidence that
TF contributes to thrombus formation and propagation in
STEMI. Our study for the first time provides direct evidence that
coagulation active TF accumulates in the coronary thrombi
isolated from patients with STEMI, thus triggering the coagulation
cascade that leads to coronary thrombosis. Two prior studies have
shown the presence of TF antigen within thrombi harvested from
coronary arteries of patients with STEMI, but none of them
demonstrated TF activity, thus leaving undetermined whether TF
may contribute to thrombus growth in this particular setting
[18,19]. Our findings may have important pathophysiological and
clinical implications, suggesting that TF blockade may be an
effective therapeutic strategy to prevent coronary thrombosis.
An important question raised by our study concerns the source
of TF. TF is normally separated from the blood by the vascular
endothelium [10]. However, this paradigm has been challenged by
the demonstration that TF is also present in circulating blood
Tissue Factor in STEMI
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[20,21,22]. Our study was not designed to address the source of
TF found within coronary thrombi, and therefore no conclusion
can be drawn from our findings. However, although we cannot
exclude the vessel wall or the ruptured plaque as the source of TF,
the distribution of TF within thrombi, in close contact with platelet
aggregates or inflammatory cells suggests that at least in part, some
of TF that is present in thrombus may be blood borne. Thus,
cryptic circulating TF may be recruited and become biologically
Table 1. Baseline clinical characteristics of patients recruited in the study.
Age, years 67 (58–75)
Male 63.2% (12/19)
History of CAD 26.3% (5/19)
Hypertension 57.9% (11/19)
Diabetes mellitus 21.1% (4/19)
Hypercholesterolemia 46.6% (7/19)
Smoking 63.2% (12/19)
Prior MI 0.0% (0/19)
Prior PCI 0.0% (0/19)
Peripheral vascular disease 0.0% (0/19)
Renal dysfunction 0.0% (0/19)
Left ventricular ejection fraction 45% (40%–55%)




Access site Femoral 57.9% (11/19)
Radial 42.1% (8/19)
Total ischemic time (mins)* 150 (108.5–450.5)
MI site Anterior 68.4% (13/19)
Inferior 31.6% (6/19)
Culprit artery LAD 68.4% (13/19)
RCA 21.1% (4/19)
Cx 10.5% (2/19)
Number of diseased vessel 1.460.6
Number of treated vessels 1.160.5
Pre-procedural TIMI flow=0 100% (19/19)
Post-procedural TIMI flow 0/I 0.0% (0/19)
II 15.8% (3/19)
III 84.2% (16/19)
Treatment with bare metal stents 94.7% (18/19)
Treatment with drug-eluting stents 5.3% (1/16)
Therapy at hospital admission Aspirin 10.5% (2/19)
Beta blockers 10.5% (2/19)
ACE inhibitors 36.8% (7/19)
ARBs 15.8% (3/19)
Calcium antagonist 15.8% (3/19)
Diuretics 21.1% (4/19)
Statins 5.3% (1/19)
Proton pump inhibitors 5.3% (1/19)
Intraprocedural therapy Intravenous aspirin 100% (19/19)
UFH (70 UI/Kg) 100% (19/19)
Glycoprotein IIb/IIIa inhibitor 100% (19/19)
Continuous data are presented as median (interquartile range). MI denotes myocardial infarction; CAD denotes coronary artery disease; PCI denotes percutaneous
coronary intervention; LAD denotes left anterior descending coronary artery; RCA denotes right coronary artery; Cx denotes circumflex artery; UFH denotes
unfractionated heparin.
*total ischemic time denotes time from symptom onset to balloon dilatation in minutes.
doi:10.1371/journal.pone.0081501.t001
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active at site of thrombus formation, thus contributing to its
growth and propagation. This hypothesis is consistent with
experimental studies that have demonstrated incorporation of
active circulating TF in growing thrombi generated in animal
models [23], or in ex-vivo perfusion systems [20,21,24]. Recent
data have also suggested that monocytes and possible granulocytes
are possible sources of circulating TF [25]. Leukocytes can transfer
TF to platelets via CD15 receptors, forming highly procoagulant
platelet aggregates containing leukocyte-derived TF [26]. In
addition, Camera et al. have suggested that platelets themselves
are able to express functionally active TF, making them capable of
triggering the coagulation cascade [27,28,29]. Of note, in our
study TF staining was noted in close contact and within platelet
aggregates, suggesting that platelets play an important role in
supporting TF-dependent coagulation.
TF activity within coronary thrombi varied greatly across
samples, possibly reflecting variable distribution of TF within
coronary thrombi, and aspiration of only part of the total volume
of thrombi. Of note, in 2 cases we could not demonstrate the
presence of TF by immunoprecipitation, even though TF could be
Figure 1. Histological assessment of thrombi aspirated from coronary arteries of patients with ST-segment elevation acute
myocardial infarction. (A) Hematoxylin and eosin staining shows platelet aggregates (*) intermingled in a fibrin network (u) with red and white
blood cells. Original magnification 100x. (B) and (C) Immunohistochemistry of coronary thrombi prepared with anti-TF CD142 antibody showing large
and irregular areas of tissue factor staining (brown colour) within platelet aggregates and white blood cells. Some portion of the platelet aggregates
stained intensely (*), whereas other lightly (++) with anti-TF CD142 antibody. B: original magnification 200x; C: original magnification 400x. (D) Detail
of a coronary thrombus showing tissue factor staining in close contact with platelet aggregates (*). Some areas of these platelet aggregates do not
display tissue factor staining (++). Monocyte are strongly positive for tissue factor, granulocytes display a weak and irregular staining, and red cells are
negative. Original magnification 400x. (E) Negative control for TF performed with immunoperoxidase staining on sections not incubated with the
primary antibody against TF. Magnification 100x. (F) Negative control using an isotype-matched irrelevant primary antibody (mouse IgG anti-
epithelial membrane antigen).
doi:10.1371/journal.pone.0081501.g001
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measured by the clotting assay. Moreover, no significant
correlation between TF antigen and TF activity was apparent,
confirming our previous finding that very little TF is required for
coagulation activity [16].
Intriguingly, both the procoagulant and the signalling confor-
mation of TF were found within coronary thrombi, as demon-
strated by 10H10 staining [16]. This finding may explain the
absence of correlation between TF activity measured with clotting
assays and TF antigen identified with immunoblotting. TF has in
fact alternative conformations with distinct functional properties
depending on the surface accessible, extracellular Cys186–Cys209
disulfide bond [16]. The non-coagulant cryptic conformation of
TF mediates PAR2-dependent TF/VIIa signalling [30]. Of note,
in our study TF staining within coronary thrombi using 10H10
displayed a similar pattern as with CD142 staining. Some
experimental studies have suggested that TF-dependent PAR2-
activation may increase infarct size in a mouse model of cardiac
ischemia/reperfusion injury [31]. Based on our previous study
demonstrating two antigenically distinct conformations of TF
recognized by the two mAbs 5G9 and 10H10 [16], we propose
that both pools of TF are present in the thrombi isolated from
patient with STEMI. Further studies are warranted to investigate
the role and the source of these two pools of TF.
This study has some limitations that should be acknowledged.
Because thrombi were retrieved by an aspiration catheter, we
could analyze only large aspirated pieces, and not the total volume
of the occlusive thrombi. The study had several exclusion criteria
and therefore whether our findings may be extrapolated to all
STEMI patients is unknown. The absence of successful throm-
boaspiration in all STEMI patients may also have biased our
results. We used TBS as control for 5G9 specificity. However, an
isotype-matched control antibody would have been more appro-
priate. We did not investigates the source of TF and therefore
further study is warranted to address this issue. All patients were
treated with bare metal stents and clopidogrel, which do not
represent any more the standard of care for patients with STEMI,
meta-analysis and randomized trials suggesting that second
generation drug-eluting stents [32], and new and more potent
antiplatelet therapies [33,34] might significantly improve the
outcomes of this high risk cohort of patients.
In conclusion, our study clearly demonstrates the presence of
active TF within coronary thrombi of patients with STEMI,
suggesting that TF may contribute in triggering the coagulation
cascade that ultimately leads to coronary thrombosis development.
Figure 2. Immunohistochemistry of coronary thrombi. (A,B and C) Immunohistochemistry prepared with 10H10 showing large and irregular
areas of tissue factor staining (in brown) within platelet aggregates and inflammatory cells. Some platelet aggregates stained positive for tissue factor
(*), whereas other did not (++). Original magnification is6200. (D) Detail of a coronary thrombus prepared with 10H10. Monocytes are strongly
positive for tissue factor, granulocytes display a weak and irregular staining, and red cells are negative. Original magnification is6400.
doi:10.1371/journal.pone.0081501.g002
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Figure 3. Clotting times measured with the modified aPTT test. (A) Clotting times of plasma samples incubated with buffer, 5G9, 10H10 or
IgG. (B) Clotting times of plasma samples containing homogenized thrombi incubated with or without 5G9. (C) Pairwise comparison of clotting times
of plasma samples containing homogenized thrombi incubated with or without 5G9. (D) Differences in clotting times between plasma samples
containing homogeneized thrombi incubated with or without 5G9.
doi:10.1371/journal.pone.0081501.g003
Table 2. Clotting times and densitometric quantification of tissue factor in coronary thrombi of patients included in the study.
Clotting times of
homogenized thrombi




Densitometric quantification of TF by
immunoprecipitation (AU)
Patient 1 75.6 85.8 10.2 NA
Patient 2 6.4 8.0 1.6 3,764
Patient 3 68.9 75.1 6.2 NA
Patient 4 8.0 8.9 0.9 1,943
Patient 5 126.9 126.1 20.8 1,023
Patient 6 76.5 75.6 20.9 4,660
Patient 7 8.4 70.9 62.6 9,200
Patient 8 63.9 68.1 4.2 219
Patient 9 114.1 121.4 7.3 10,219
Patient 10 6.6 96.7 90.1 36,457
Patient 11 84.5 88.9 4.4 4,710
Patient 12 106.0 113.9 7.9 NA
Patient 13 83.0 98.4 15.4 5,640
Patient 14 88.7 100.8 12.1 9,091
Patient 15 125.2 160.0 34.8 155
Clotting times are provided in seconds; AU denotes arbitrary unit; NA denotes not available.
doi:10.1371/journal.pone.0081501.t002
Tissue Factor in STEMI
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